Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2019
  • 2023
  • 2022
  • 2021
  • 2020
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
December 30, 2019

New number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
December 30, 2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019

Regulatory
December 9, 2019

Final result of the rights issue in Oasmia

Regulatory
December 6, 2019

Oasmia’s rights issue has been oversubscribed

Non Regulatory
November 27, 2019

Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue

Non Regulatory
November 27, 2019

The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue

Regulatory
November 19, 2019

Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus

Non Regulatory
November 18, 2019

Oasmia invites to investor meetings in connection to the rights issue

Regulatory
November 11, 2019

Oasmia resolves on a rights issue of approximately SEK 399 million

Regulatory
November 6, 2019

Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019

Regulatory
October 30, 2019

Oasmia recruits Michael af Winklerfelt as new CFO

Regulatory
October 14, 2019

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

Regulatory
October 14, 2019

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million

Regulatory
September 26, 2019

Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019

Regulatory
September 26, 2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019

Regulatory
September 18, 2019

Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte

Non Regulatory
September 18, 2019

Oasmia presents Q1 report through audiocast on September 26

Regulatory
September 15, 2019

The Nomination Committee’s proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019

Regulatory
September 5, 2019

Oasmia publishes its annual report and adjusts accounts due to write-downs

Non Regulatory
September 4, 2019

Oasmia completes its management team

Regulatory
August 28, 2019

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
August 27, 2019

Oasmia updates regarding MGC disputes

Regulatory
August 23, 2019

Oasmia ADSs delisted from NASDAQ in the US

Regulatory
August 20, 2019

Nomination committee in Oasmia for the 2019 AGM

Regulatory
August 15, 2019

Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calender

Non Regulatory
August 2, 2019

Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs

Regulatory
July 31, 2019

New number of shares and votes in Oasmia Pharmaceutical AB (publ)

Non Regulatory
July 9, 2019

Oasmia discontinues cooperation with former executive chairman

Regulatory
July 5, 2019

Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia

Regulatory
July 4, 2019

Oasmia appoints Business Advisory Board

Regulatory
July 2, 2019

Oasmia appoints new CMO

Regulatory
July 2, 2019

Oasmia appoints Scientific Advisory Board

Regulatory
June 28, 2019

Oasmia announces change of CEO

Regulatory
June 28, 2019

The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner

Regulatory
June 28, 2019

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019

Non Regulatory
June 26, 2019

Oasmia presents full-year report and status in the Board’s review through audiocast on June 28

Regulatory
June 25, 2019

Two studies finalized in Oasmia Pharmaceutical’s Docecal programme

Regulatory
May 15, 2019

Oasmia postpones the release of the Q4 and year-end report to 28 June

Regulatory
April 10, 2019

Oasmia expands the Management Team

Non Regulatory
April 3, 2019

Short report of the status of the review in Oasmia

Regulatory
March 29, 2019

Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Non Regulatory
March 28, 2019

The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.

Non Regulatory
March 26, 2019

Notification from Oasmia Pharmaceutical AB

Regulatory
March 26, 2019

CFO of Oasmia, Anders Blom has resigned

Regulatory
March 25, 2019

Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information

Regulatory
March 21, 2019

New Board starts reviewing the situation in Oasmia

Regulatory
March 19, 2019

Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019

Regulatory
March 18, 2019

Oasmia announces a prospectus regarding admission to trading of new shares

Regulatory
March 6, 2019

Oasmia Pharmaceutical Strengthens its Management Team and Organization

Regulatory
March 4, 2019

Oasmia has completed a directed share issue of approximately 165 MSEK

Regulatory
March 1, 2019

Oasmia Pharmaceutical AB (publ)

Regulatory
February 5, 2019

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

Regulatory
January 31, 2019

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
January 22, 2019

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019

Regulatory
January 21, 2019

Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled

Regulatory
January 15, 2019

European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer.

The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval.

Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Moreover, the company is developing Paccal Vet (paclitaxel micellar) for malignant melanoma and hemangiosarcoma in dogs. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com